OHM20, seeing as you are up-periscope at the moment, and
OHM20, seeing as you are up-periscope at the moment, and speaking of the HIV monotherapy trial, with reference to current company protocols under development it strikes me that monotherapy overlap with NASH/NAFLD would definitely qualify as fast track and unmet need, potentially breakthrough designation…priority target acquired. The question I have is whether you have given any thought to 700 mg dosing for monotherapy reflected against clearer NASH results at 350mg. Recognizing the need to be more bullet-proof for monotherapy the higher dose is going to prevail in the protocol. Do you think the 700 mg for NASH can be made to sing by things like haplotype inclusion criteria, upping number to treat or other factors? I’m sure Recknor is in the weeds with this, and hope they give us some specifics at the ASM…would love to do a Spock mind-meld with that guy. Any thoughts?
5
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Jushi Holdings Inc. to Announce Financial Results BOCA RATON, Fla. -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF), a well-established player in the cannabis industry, is gearing up to share its financial performance for the second quarter. This key announcement will take place after market hours on the fifth day of August. Details for...
Continue Reading
Mike Tyson's Exciting Role with BoltBetz BoltBetz, known for revolutionizing cashless gaming technology, has recently announced a significant partnership with the legendary boxing champion Mike Tyson. With Tyson as both a strategic investor and promotional partner, this collaboration promises to transform the landscape of gaming across various casinos. Tyson's entry into...
Continue Reading
Portage Community Bank Appoints New Executive Leader Portage Community Bank is thrilled to announce the appointment of C. Joseph Assid as the new Executive Vice President and Chief Financial Officer. With a rich experience spanning over twenty-five years in financial institution accounting, audit, and assurance services, Mr. Assid brings invaluable expertise to this...
Continue Reading
Angelalign Technology Inc., listed as 6699.HK on the Hong Kong Stock Exchange, is heading back to court—this time, challenging a ruling from the Jinan Intermediate People's Court in China. They aim to overturn a judgment that ordered their subsidiaries to stop using key systems like the masterForce biomechanics simulation and the ATreat digital diagnosis system for...
Continue Reading
Unicycive Therapeutics Investigated for Potential Claims Investors holding securities in Unicycive Therapeutics, Inc. are facing an important deadline for potential legal actions. The company, listed on NASDAQ as UNCY, has come under scrutiny, and it's essential for affected investors to understand their options moving forward. Who Should Be Concerned? If you acquired...
Continue Reading
